Skip to main content

Gen Digital Inc.

For the period ended Jan 2, 2026. Filed Feb 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jan 2, 2026 · Filed Feb 6, 2026

GEN$30.01+0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited, in millions, except share amounts)

Three months ended January 2, 2026 · Common Stock and Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · Retained Earnings (Accumulated Deficit) · Total Stockholders’ Equity (Deficit)
Shares · Amount
Balance as of October 3, 2025617$2,236$4$217$2,457
Net income (loss)———192192
Other comprehensive income (loss), net of taxes——15—15
Shares withheld for taxes related to vesting of stock units—(4)——(4)
Repurchases of common stock (1)(11)(3)—(300)(303)
Cash dividends declared ($0.125 per share of common stock) and dividend equivalents accrued—(2)—(77)(79)
Stock-based compensation—54——54
Balance as of January 2, 2026606$2,281$19$32$2,332
Nine months ended January 2, 2026 · Common Stock and Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · Retained Earnings (Accumulated Deficit) · Total Stockholders’ Equity (Deficit)
Shares · Amount
Balance as of March 28, 2025617$2,066$(33)$236$2,269
Net income (loss)———461461
Other comprehensive income (loss), net of taxes——52—52
Common stock issued under employee stock incentive plans77——7
Shares withheld for taxes related to vesting of stock units(2)(52)——(52)
Repurchases of common stock (1)(16)(3)—(434)(437)
Cash dividends declared ($0.375 per share of common stock) and dividend equivalents accrued—(7)—(231)(238)
Stock-based compensation—176——176
Fair value of replacement awards issued in connection with business acquisitions—21——21
Fair value of CVR issued in connection with business acquisitions—73——73
Balance as of January 2, 2026606$2,281$19$32$2,332

(1) Amount includes excise tax on share repurchases.

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited, in millions, except share amounts)

Three months ended December 27, 2024 · Common Stock and Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · Retained Earnings (Accumulated Deficit) · Total Stockholders’ Equity (Deficit)
Shares · Amount
Balance as of September 27, 2024616$1,995$14$89$2,098
Net income (loss)———159159
Other comprehensive income (loss), net of taxes——(60)—(60)
Cash dividends declared ($0.125 per share of common stock) and dividend equivalents accrued—(2)—(77)(79)
Stock-based compensation—33——33
Balance as of December 27, 2024616$2,026$(46)$171$2,151
Nine months ended December 27, 2024 · Common Stock and Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · Retained Earnings (Accumulated Deficit) · Total Stockholders’ Equity (Deficit)
Shares · Amount
Balance as of March 29, 2024623$2,227$11$(98)$2,140
Net income (loss)———501501
Other comprehensive income (loss), net of taxes——(57)—(57)
Common stock issued under employee stock incentive plans56——6
Shares withheld for taxes related to vesting of restricted stock units(1)(25)——(25)
Repurchases of common stock (1)(11)(274)——(274)
Cash dividends declared ($0.375 per share of common stock) and dividend equivalents accrued—(5)—(232)(237)
Stock-based compensation—97——97
Balance as of December 27, 2024616$2,026$(46)$171$2,151

(1)Amount includes excise tax on share repurchases.

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.